Pharmaids Pharmaceuticals VP resigns citing personal reasons

1 min read Updated on 25 Jun 2026, 07:09 PM

Reviewed by

Shriram SScanX News Team

AI Summary

Pharmaids Pharmaceuticals Limited accepted the resignation of Dr. Jagadeesh M N as Vice President – Discovery Services effective June 25, 2026, due to personal reasons. The disclosure was filed with BSE under Regulation 30 of the SEBI Listing Regulations.

*this image is generated using AI for illustrative purposes only.

Pharmaids Pharmaceuticals Limited has accepted the resignation of Dr. Jagadeesh M N from the position of Vice President – Discovery Services. The resignation, effective from the close of business hours on June 25, 2026, was submitted due to personal reasons. This development impacts the company's senior management structure within its discovery services division.

The disclosure was made to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the necessary details, including the resignation letter, have been submitted as required under the regulations read with the SEBI Master Circular dated January 30, 2026.

Venu Madhava Kaparthy, Whole-time Director of Pharmaids Pharmaceuticals Limited, signed the regulatory filing. The resignation letter addressed to the Board of Directors expressed gratitude to the board and wished the company well for the future. The information has been made available on the company's official website.

The following table outlines the key details of the management change:

Particulars	Details
Reason for change	Resignation due to personal reasons
Date of cessation	June 25, 2026
Brief profile	Not Applicable
Relationship disclosure	Not Applicable

Historical Stock Returns for Pharmaids Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.76%	-0.23%	+18.93%	-26.35%	-42.72%	+151.73%

Who will be appointed to replace Dr. Jagadeesh M N, and how will this transition affect ongoing discovery projects?

What is the timeline for announcing a successor, and will an interim leadership structure be implemented?

How might this leadership change impact Pharmaids' strategic priorities in the discovery services division?

Read Next Article

Pharmaids Pharmaceuticals issues ₹55 Lakhs guarantee to subsidiary

2 min read Updated on 13 Jun 2026, 10:16 AM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

Pharmaids Pharmaceuticals Ltd has issued a corporate guarantee of ₹55 Lakhs to its unlisted material subsidiary, Adita Bio Sys Private Limited. The guarantee secures a loan facility availed under the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0 from State Bank of India. The Board of Directors had previously approved a guarantee limit not exceeding ₹75 Lakhs for this purpose.

*this image is generated using AI for illustrative purposes only.

Pharmaids Pharmaceuticals Limited has issued a corporate guarantee of ₹55 Lakhs to its unlisted material subsidiary, Adita Bio Sys Private Limited. The guarantee was provided to secure a new loan facility availed by the subsidiary under the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0, an initiative by the Government of India. The facility has been sanctioned by State Bank of India, SME Branch, located in Tumkur.

The Board of Directors of Pharmaids Pharmaceuticals Limited, at its meeting held on May 29, 2026, had approved the provision of a corporate guarantee to banks or financial institutions. The approval covered a loan amount not exceeding ₹75 Lakhs proposed to be availed by Adita Bio Sys Private Limited. The actual guarantee agreement of ₹55 Lakhs was entered into with the bank on the intimation date.

The disclosure was made to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirmed that the promoter, promoter group, or group companies do not have any interest in this transaction.

The corporate guarantee is classified as a contingent liability for Pharmaids Pharmaceuticals Limited. The company stated that the guarantee has been provided on behalf of a subsidiary which is part of the consolidated group, and presently, there is no financial impact on the company resulting from this arrangement.

The following table outlines the key details of the guarantee:

S No	Particulars	Details
a.	Name of party for which guarantee was given	Adita Bio Sys Private Limited (“Adita”), an unlisted material subsidiary of the Company. (“Borrower”)
b.	Whether the promoter/ promoter group/ group companies have any interest in this transaction?	The promoter/ promoter group/ group companies do not have any interest in this transaction.
c.	Brief details of guarantee	The Company at its Board Meeting held on May 29, 2026 had approved to provide Corporate Guarantee to any Banks/ Financial Institutions for a new loan facility for an amount not exceeding Rs. 75,00,000/- (Rupees Seventy-Five Lakhs only), proposed to be availed by Adita, pursuant to Emergency Credit Line Guarantee Scheme (ECLGS) 5.0, an initiative by Govt of India, subject to the terms of the sanction letter issued by such Banks/ Financial Institutions. The Corporate Guarantee Agreement of Rs. 55,00,000 (Rupees Fifty-Five Lakhs only) in favour of State Bank of India, SME Branch, 4th Cross, Ashok Nagar, Tumkur (“Bank”), to secure the new loan facility under ECLGS 5.0 availed by Adita, has been entered into by the Company and the Bank, on the intimation date.
d.	Impact of such guarantees on listed entity	The Corporate Guarantee provided is a contingent liability for the Company. This guarantee has been provided on behalf of a subsidiary of the Company which is part of the consolidated group. Presently, there is no impact of this guarantee on the Company.